-
-
-
-
-
-
-
Jazz Pharmaceuticals (JAZZ) Tops Q1 EPS by 172c; offers guidance
-
-
-
-
-
-
-
Jazz Pharmaceuticals (JAZZ) Tops Q3 EPS by $2.20, provides guidance
-
-
-
-
-
-
-
Jazz Pharmaceuticals Names Renee Gala as President and Chief Executive Officer
-
-
-
-
-
-
-
Biotech sector Q1 earnings preview from RBC Capital Markets
-
-
-
-
-
-
-
Jazz Pharmaceuticals (JAZZ) PT Raised to $162 at Baird
-
-
-
-
-
-
-
Ligand Reports First Quarter 2024 Financial Results
-
-
-
-
-
-
-
Jazz Pharmaceuticals (JAZZ) Misses Q3 EPS by 9c; Offers FY23 EPS Guidance
-
1,218,206 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

